A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease

被引:54
|
作者
Hu, MTM
White, SJ
Herlihy, AH
Chaudhuri, KR
Hajnal, JV
Brooks, DJ
机构
[1] Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England
[2] Hammersmith Hosp, Imperial Coll, Sch Med, Div Neurosci, London W12 0NN, England
[3] Hammersmith Hosp, Imperial Coll, Sch Med, Robert Steiner MR Unit, London W12 0NN, England
[4] Guys Kings & St Thomas Sch Med, Dept Neurol, Movement Disorders Unit, London, England
[5] Kings Coll London, Inst Psychiat, London WC2R 2LS, England
[6] Univ Hosp Lewisham, Lewisham, England
[7] Inst Neurol, London WC1N 3BG, England
关键词
D O I
10.1212/WNL.56.9.1195
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To quantify structural changes in the substantia nigra of patients with PD with inversion recovery MRI and to compare these with striatal dopaminergic function measured with F-18-dopa PET. Methods: The authors studied 10 patients with PD and eight age-matched control subjects with a combination of MR sequences previously reported to be sensitive to nigral cell loss. Striatal regions of interest were defined on T1-weighted MRI coregistered to F-18-dopa PET in all subjects. Results: Discriminant function analysis of the quantified MR nigral signal correctly classified 83% of the combined PD patient/control group; three of 10 PD cases were incorrectly classified as "normal" (Wilks' lambda = 0.724, p > 0.05). Discriminant function analysis correctly classified 100% of PD patients and control subjects with F-18-dopa PET based on mean caudate and putamen K-i values (Wilks' lambda = 0.065, p < 0.001). Correlations between mean putamen K-i and rostral and caudal nigral MR signal changes and mean caudate K-i and caudal nigral MR signal changes were found (r = -0.76, -0.69, -0.80, p < 0.05). Conclusion: F-18-dopa PET is more reliable than inversion recovery MRI in discriminating patients with moderately severe PD from normal subjects. However, the structural changes detected within the substantia nigra of patients with PD found using inversion recovery MRI correlate with measures of striatal dopaminergic function using F-18-dopa PET.
引用
收藏
页码:1195 / 1200
页数:6
相关论文
共 50 条
  • [31] Lateralisation of striatal function:: evidence from 18F-dopa PET in Parkinsion's disease
    Cheesman, AL
    Barker, RA
    Lewis, SJG
    Robbins, TW
    Owen, AM
    Brooks, DJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (09): : 1204 - 1210
  • [32] Biodistribution considerations on 18F-DOPA PET/CT
    Chondrogiannis, Sotirios
    Marzola, Maria Cristina
    Grassetto, Gaia
    Rampin, Lucia
    Massaro, Arianna
    Ferretti, Alice
    Fornasiero, Adrian
    Rubello, Domenico
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [33] STRIATAL DOPAMINERGIC DEGENERATION AND MOTOR AND COGNITIVE SYMPTOMS IN DE NOVO PARKINSON'S DISEASE: AN 18F-DOPA PET STUDY
    De Meyer, E.
    Meles, S.
    Van der Zee, S.
    Carli, G.
    Slomp, A.
    Slingerland, S.
    Goethals, I.
    Dierckx, R.
    Van Laar, T.
    [J]. PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [34] 18F-DOPA PET/CT FOR CONGENITAL HYPERINSULINISM
    Campbell, L.
    Garcia, P.
    [J]. INTERNAL MEDICINE JOURNAL, 2011, 41 : 4 - 4
  • [35] Carcinoid recurrence tumor and 18F-DOPA PET
    Cavet, M.
    Tenenbaum, F.
    Hignette, C.
    Modis, C.
    Richard, B.
    Faraggi, M.
    Dousset, B.
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 (03): : 213 - 217
  • [36] 18F-DOPA PET/CT and neuroendocrine tumours
    Nanni, C
    Rubello, D
    Fanti, S
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (05) : 509 - 513
  • [37] 18F-DOPA PET/CT and neuroendocrine tumours
    Cristina Nanni
    Domenico Rubello
    Stefano Fanti
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 509 - 513
  • [38] Radionecrosis versus disease progression in brain metastasis. Value of 18F-DOPA PET/CT/MRI
    Hernandez Pinzon, J.
    Mena, D.
    Aguilar, M.
    Biafore, F.
    Recondo, G.
    Bastianello, M.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (05): : 332 - 335
  • [39] Longitudinal comparison of 11C-PE2I and 18F-DOPA pet for assessing severity and rate of disease progression in patients with Parkinson's disease
    Li, W.
    Lao-Kaim, N. P.
    Roussakis, A.
    Martin-Bastida, A.
    Loane, C.
    Valle-Guzman, N.
    Kefalopoulou, Z.
    Politis, M.
    Foltynie, T.
    Barker, R. A.
    Piccini, P.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 128 - 128
  • [40] Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson's disease
    Li, W.
    Lao-Kaim, N.
    Roussakis, A. -A.
    Martin-Bastida, A.
    Loane, C.
    Valle-Guzman, N.
    Kefalopoulou, Z.
    Politis, M.
    Foltynie, T.
    Barker, R.
    Piccini, P.
    [J]. MOVEMENT DISORDERS, 2017, 32